Cargando…

Activator protein-1 (AP-1) signalling in human atherosclerosis: results of a systematic evaluation and intervention study

Animal studies implicate the AP-1 (activator protein-1) pro-inflammatory pathway as a promising target in the treatment of atherosclerotic disease. It is, however, unclear whether these observations apply to human atherosclerosis. Therefore we evaluated the profile of AP-1 activation through histolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Meijer, C. Arnoud, Le Haen, Pum A. A., van Dijk, Rogier A., Hira, Mitsuhisa, Hamming, Jaap F., van Bockel, J. Hajo, Lindeman, Jan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259695/
https://www.ncbi.nlm.nih.gov/pubmed/22092038
http://dx.doi.org/10.1042/CS20110234
_version_ 1782221414854557696
author Meijer, C. Arnoud
Le Haen, Pum A. A.
van Dijk, Rogier A.
Hira, Mitsuhisa
Hamming, Jaap F.
van Bockel, J. Hajo
Lindeman, Jan H.
author_facet Meijer, C. Arnoud
Le Haen, Pum A. A.
van Dijk, Rogier A.
Hira, Mitsuhisa
Hamming, Jaap F.
van Bockel, J. Hajo
Lindeman, Jan H.
author_sort Meijer, C. Arnoud
collection PubMed
description Animal studies implicate the AP-1 (activator protein-1) pro-inflammatory pathway as a promising target in the treatment of atherosclerotic disease. It is, however, unclear whether these observations apply to human atherosclerosis. Therefore we evaluated the profile of AP-1 activation through histological analysis and tested the potential benefit of AP-1 inhibition in a clinical trial. AP-1 activation was quantified by phospho-c-Jun nuclear translocation (immunohistochemistry) on a biobank of aortic wall samples from organ donors. The effect of AP-1 inhibition on vascular parameters was tested through a double blind placebo-controlled cross-over study of 28 days doxycycline or placebo in patients with symptomatic peripheral artery disease. Vascular function was assessed by brachial dilation as well as by plasma samples analysed for hs-CRP (high-sensitivity C-reactive protein), IL-6 (interleukin-6), IL-8, ICAM-1 (intercellular adhesion molecule-1), vWF (von Willebrand factor), MCP-1 (monocyte chemoattractant protein-1), PAI-1 (plasminogen activator inhibitor-1) and fibrinogen. Histological evaluation of human atherosclerosis showed minimal AP-1 activation in non-diseased arterial wall (i.e. vessel wall without any signs of atherosclerotic disease). A gradual increase of AP-1 activation was found in non-progressive and progressive phases of atherosclerosis respectively (P<0.044). No significant difference was found between progressive and vulnerable lesions. The expression of phospho-c-Jun diminished as the lesion stabilized (P<0.016) and does not significantly differ from the normal aortic wall (P<0.33). Evaluation of the doxycycline intervention only revealed a borderline-significant reduction of circulating hs-CRP levels (−0.51 μg/ml, P=0.05) and did not affect any of the other markers of systemic inflammation and vascular function. Our studies do not characterize AP-1 as a therapeutic target for progressive human atherosclerotic disease.
format Online
Article
Text
id pubmed-3259695
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-32596952012-01-18 Activator protein-1 (AP-1) signalling in human atherosclerosis: results of a systematic evaluation and intervention study Meijer, C. Arnoud Le Haen, Pum A. A. van Dijk, Rogier A. Hira, Mitsuhisa Hamming, Jaap F. van Bockel, J. Hajo Lindeman, Jan H. Clin Sci (Lond) Research Article Animal studies implicate the AP-1 (activator protein-1) pro-inflammatory pathway as a promising target in the treatment of atherosclerotic disease. It is, however, unclear whether these observations apply to human atherosclerosis. Therefore we evaluated the profile of AP-1 activation through histological analysis and tested the potential benefit of AP-1 inhibition in a clinical trial. AP-1 activation was quantified by phospho-c-Jun nuclear translocation (immunohistochemistry) on a biobank of aortic wall samples from organ donors. The effect of AP-1 inhibition on vascular parameters was tested through a double blind placebo-controlled cross-over study of 28 days doxycycline or placebo in patients with symptomatic peripheral artery disease. Vascular function was assessed by brachial dilation as well as by plasma samples analysed for hs-CRP (high-sensitivity C-reactive protein), IL-6 (interleukin-6), IL-8, ICAM-1 (intercellular adhesion molecule-1), vWF (von Willebrand factor), MCP-1 (monocyte chemoattractant protein-1), PAI-1 (plasminogen activator inhibitor-1) and fibrinogen. Histological evaluation of human atherosclerosis showed minimal AP-1 activation in non-diseased arterial wall (i.e. vessel wall without any signs of atherosclerotic disease). A gradual increase of AP-1 activation was found in non-progressive and progressive phases of atherosclerosis respectively (P<0.044). No significant difference was found between progressive and vulnerable lesions. The expression of phospho-c-Jun diminished as the lesion stabilized (P<0.016) and does not significantly differ from the normal aortic wall (P<0.33). Evaluation of the doxycycline intervention only revealed a borderline-significant reduction of circulating hs-CRP levels (−0.51 μg/ml, P=0.05) and did not affect any of the other markers of systemic inflammation and vascular function. Our studies do not characterize AP-1 as a therapeutic target for progressive human atherosclerotic disease. Portland Press Ltd. 2012-01-16 2012-05-01 /pmc/articles/PMC3259695/ /pubmed/22092038 http://dx.doi.org/10.1042/CS20110234 Text en © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by-nc/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Meijer, C. Arnoud
Le Haen, Pum A. A.
van Dijk, Rogier A.
Hira, Mitsuhisa
Hamming, Jaap F.
van Bockel, J. Hajo
Lindeman, Jan H.
Activator protein-1 (AP-1) signalling in human atherosclerosis: results of a systematic evaluation and intervention study
title Activator protein-1 (AP-1) signalling in human atherosclerosis: results of a systematic evaluation and intervention study
title_full Activator protein-1 (AP-1) signalling in human atherosclerosis: results of a systematic evaluation and intervention study
title_fullStr Activator protein-1 (AP-1) signalling in human atherosclerosis: results of a systematic evaluation and intervention study
title_full_unstemmed Activator protein-1 (AP-1) signalling in human atherosclerosis: results of a systematic evaluation and intervention study
title_short Activator protein-1 (AP-1) signalling in human atherosclerosis: results of a systematic evaluation and intervention study
title_sort activator protein-1 (ap-1) signalling in human atherosclerosis: results of a systematic evaluation and intervention study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259695/
https://www.ncbi.nlm.nih.gov/pubmed/22092038
http://dx.doi.org/10.1042/CS20110234
work_keys_str_mv AT meijercarnoud activatorprotein1ap1signallinginhumanatherosclerosisresultsofasystematicevaluationandinterventionstudy
AT lehaenpumaa activatorprotein1ap1signallinginhumanatherosclerosisresultsofasystematicevaluationandinterventionstudy
AT vandijkrogiera activatorprotein1ap1signallinginhumanatherosclerosisresultsofasystematicevaluationandinterventionstudy
AT hiramitsuhisa activatorprotein1ap1signallinginhumanatherosclerosisresultsofasystematicevaluationandinterventionstudy
AT hammingjaapf activatorprotein1ap1signallinginhumanatherosclerosisresultsofasystematicevaluationandinterventionstudy
AT vanbockeljhajo activatorprotein1ap1signallinginhumanatherosclerosisresultsofasystematicevaluationandinterventionstudy
AT lindemanjanh activatorprotein1ap1signallinginhumanatherosclerosisresultsofasystematicevaluationandinterventionstudy